SURMOUNT-3 Trial: Tirzepatide After Lifestyle Intervention Produces Up to 26.6% Weight Loss

What SURMOUNT-3 Was Designed to Test

SURMOUNT-3 asked a precise question: does tirzepatide add meaningful weight loss on top of what a structured lifestyle program already achieves? Researchers enrolled 806 adults across multiple sites, required every participant to complete a 12-week low-calorie diet and behavioral counseling run-in, and only randomized those who lost at least 5% of body weight during that run-in period. This design is important because it mirrors a common clinical scenario, a patient who has "done everything right" and still wants pharmacological support to go further.

At week 72 after randomization, the tirzepatide arm lost a mean 18.4% of body weight, while the placebo arm gained back roughly 2.5% from the randomization weight [1]. Anchored to the original screening weight, cumulative losses were 26.6% for tirzepatide versus 9.4% for placebo. For context, the 26.6% figure is the largest mean weight loss reported in any Phase 3 obesity pharmacotherapy trial published to date.

The trial also reported that 89.3% of tirzepatide participants achieved at least 5% weight loss from randomization, 69.4% achieved at least 15%, and 36.2% achieved at least 25% [1]. Adverse events were consistent with prior SURMOUNT data: nausea (30.8%), diarrhea (22.3%), and vomiting (16.3%) were the most common, predominantly mild to moderate and concentrated during dose escalation.

How SURMOUNT-3 Fits Into the Broader SURMOUNT Program

Eli Lilly ran four large Phase 3 obesity trials under the SURMOUNT name, each probing a different clinical question. Reading them together gives a clearer picture than any single trial alone.

SURMOUNT-1 enrolled 2,539 adults without type 2 diabetes and randomized them to tirzepatide 5, 10, or 15 mg or placebo for 72 weeks. Mean weight loss at the 15 mg dose was 22.5% versus 2.4% for placebo [2]. The 15 mg group saw 57.3% of participants lose at least 20% of body weight, a threshold rarely approached by any prior anti-obesity medication.

SURMOUNT-2 focused on adults with type 2 diabetes, a population historically harder to treat for weight because several diabetes medications promote weight gain. In 938 participants over 72 weeks, tirzepatide 15 mg produced 15.7% mean weight loss versus 3.3% for placebo [3]. The Lancet authors noted that this magnitude of loss exceeded all prior glucose-lowering agents studied specifically for weight.

SURMOUNT-3 added the lifestyle run-in design described above, producing cumulative losses of 26.6% [1].

SURMOUNT-4 answered a maintenance question: what happens when tirzepatide is stopped? After 36 weeks of open-label tirzepatide during which participants lost 20.9% of body weight, patients were randomized to continue tirzepatide or switch to placebo for another 52 weeks. The placebo group regained 14.8 percentage points of the lost weight, while the tirzepatide continuation group lost an additional 5.5 percentage points [4]. The JAMA authors concluded that "weight loss maintenance required continued treatment," a pattern seen consistently across GLP-1 class drugs.

The combined SURMOUNT dataset supports a tiered clinical picture. Patients without diabetes lose more weight than those with it. Adding an intensive lifestyle run-in before pharmacotherapy may amplify total outcomes. And stopping the drug reliably reverses most of the benefit within one year.

The STEP Trials: Semaglutide's Evidence Base

Semaglutide 2.4 mg (Wegovy) preceded tirzepatide to market and built its case through the five-trial STEP program. Understanding each trial matters because they address genuinely different patient populations.

STEP-1 remains the foundational semaglutide obesity trial. In 1,961 adults without diabetes, semaglutide 2.4 mg once weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo (P<0.001) [5]. Roughly 86.4% of semaglutide participants lost at least 5% of body weight. The New England Journal of Medicine published these results in February 2021, and the FDA approved Wegovy three months later.

STEP-2 shifted to adults with type 2 diabetes. In 1,210 participants over 68 weeks, semaglutide 2.4 mg produced 9.6% mean weight loss versus 3.4% for placebo [6]. The lower effect size compared to STEP-1 mirrors the pattern seen in SURMOUNT: diabetes attenuates pharmacological weight loss, though the absolute reductions still exceed those of most prior agents.

STEP-3 tested whether combining semaglutide with intensive behavioral therapy added anything beyond drug alone. In 611 participants over 68 weeks, the combination arm lost 16.0% of body weight compared with 5.7% in the placebo-plus-behavioral-therapy arm [7]. The semaglutide arm outperformed placebo even when both groups received identical intensive counseling, which underscores the pharmacological contribution independent of lifestyle support.

STEP-5 is the longest semaglutide weight-loss trial published, running 104 weeks in 304 adults without diabetes. Mean weight loss was 15.2% at two years for semaglutide versus 2.6% for placebo [8]. Weight loss was largely sustained from week 20 through week 104, suggesting the drug does not lose effectiveness over two years at the approved dose.

STEP-8 moved away from placebo and ran a direct head-to-head comparison: semaglutide 2.4 mg versus liraglutide 3.0 mg over 68 weeks in 338 adults without diabetes. Semaglutide produced 15.8% mean weight loss; liraglutide produced 6.4% (P<0.001) [9]. This trial effectively established semaglutide's dominance over the first approved GLP-1 obesity drug.

Semaglutide vs. Tirzepatide: What the Trial Data Actually Shows

No head-to-head RCT comparing semaglutide 2.4 mg with tirzepatide for obesity had been published as of early 2025. Indirect comparisons from the STEP and SURMOUNT programs suggest tirzepatide produces larger weight losses, but trial populations and designs differed enough that no number-to-number comparison is fully valid.

The most-cited indirect comparison comes from SURMOUNT-1 versus STEP-1. Both enrolled adults without diabetes, both ran 72 or 68 weeks, and both used similar eligibility criteria. SURMOUNT-1 reported 22.5% mean weight loss at the 15 mg tirzepatide dose [2]; STEP-1 reported 14.9% [5]. The 7.6 percentage-point gap is substantial, but cannot be attributed to drug alone in the absence of a randomized head-to-head design.

Tirzepatide's mechanism may explain the difference. It is a dual GIP/GLP-1 receptor agonist, activating both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Semaglutide is a selective GLP-1 receptor agonist. The additive GIP receptor activity appears to enhance energy expenditure and reduce fat mass beyond GLP-1 agonism alone, based on preclinical and early human data, though the exact mechanistic contribution in humans remains under study.

The AACE/ACE clinical practice guidelines on obesity state that "the intensity of pharmacotherapy should be matched to the degree of adiposity-related risk and to the patient's response to lifestyle intervention alone" [10]. By that standard, patients who have achieved only modest weight loss with lifestyle changes alone may be candidates for either agent, with tirzepatide offering a higher ceiling for weight loss.

Cardiovascular Outcomes: The SELECT Trial and What It Adds

Weight and cardiovascular risk are connected, but the SELECT trial asked a more specific question: does semaglutide 2.4 mg reduce major adverse cardiovascular events independently of how much weight it removes? SELECT enrolled 17,604 adults with pre-existing cardiovascular disease and a BMI of at least 27, but without diabetes. At a median follow-up of 39.8 months, semaglutide reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% versus placebo (HR 0.80 to 95% CI 0.72 to 0.90, P<0.001) [11].

Dr. A. Michael Lincoff, principal investigator for SELECT, noted in the NEJM publication that "the cardiovascular benefit appeared early and persisted throughout follow-up, a pattern consistent with anti-inflammatory effects rather than weight loss alone," since meaningful weight differences between arms took months to accumulate while event curves diverged within the first year.

No equivalent cardiovascular outcomes trial for tirzepatide in people without diabetes had reported primary results as of early 2025. The SURPASS-CVOT trial is ongoing. Clinicians advising patients with established cardiovascular disease can currently cite SELECT-level evidence only for semaglutide.

Practical Dosing: What the Labels Say

The FDA-approved Wegovy label specifies semaglutide 2.4 mg once weekly subcutaneous injection, initiated at 0.25 mg weekly for four weeks, then titrated through 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg over 16 to 20 weeks [12]. The label lists a BMI threshold of 30 or greater, or 27 or greater with at least one weight-related condition (hypertension, type 2 diabetes, or dyslipidemia).

The Zepbound (tirzepatide) label specifies 5, 10, and 15 mg weekly doses, initiated at 2.5 mg for four weeks, then increasing by 2.5 mg every four weeks as tolerated [13]. The same BMI criteria apply. Both labels carry boxed warnings regarding a potential risk of thyroid C-cell tumors observed in rodent studies; neither drug is approved for use with a personal or family history of medullary thyroid carcinoma or MEN2.

Tirzepatide's dose escalation takes a minimum of 20 weeks to reach the 15 mg maintenance dose. In SURMOUNT-3, the majority of patients who completed the trial were receiving 10 or 15 mg, the two doses associated with the largest weight reductions in SURMOUNT-1.

Patient Selection: Who Benefits Most From Each Trial's Population

The STEP and SURMOUNT trials together define several clinical subgroups worth distinguishing.

Adults without type 2 diabetes and BMI ≥30 showed the strongest absolute weight loss in both programs. STEP-1 and SURMOUNT-1 are the most applicable trials for this group. If a patient has already completed a structured lifestyle program and wants the highest achievable pharmacological weight reduction, SURMOUNT-3 is the most directly relevant data point.

Adults with type 2 diabetes lose less weight on average. STEP-2 (9.6% with semaglutide) and SURMOUNT-2 (15.7% with tirzepatide 15 mg) both show real but attenuated responses [3][6]. For these patients, tirzepatide carries an additional advantage: it is also approved as Mounjaro for type 2 diabetes management, meaning a single drug addresses both conditions.

Long-term maintenance is non-negotiable based on SURMOUNT-4 and STEP-5. SURMOUNT-4 showed 14.8 percentage points of regain within 52 weeks of stopping tirzepatide [4]. STEP-5 showed that two years of continuous semaglutide maintained approximately the same weight loss as was seen at 20 weeks [8]. The clinical implication is that both drugs require ongoing prescribing plans rather than finite courses.

Patients with established cardiovascular disease and no diabetes represent a group where SELECT data provides a strong rationale for semaglutide specifically. A 20% reduction in MACE over roughly three years is a hard endpoint that no current tirzepatide trial has yet replicated in this population [11].

Adverse Effects Across the Trial Programs

Gastrointestinal events dominate the adverse effect profile of both drugs. In SURMOUNT-1, nausea affected 31.1% of the 15 mg tirzepatide group [2]. In STEP-1, nausea affected 44.2% of the semaglutide group [5]. Most events were mild to moderate and resolved after the dose-escalation phase. Serious adverse events leading to discontinuation occurred in 4.3% of tirzepatide patients in SURMOUNT-1 and in approximately 7% of semaglutide patients in STEP-1.

Gallbladder disease appeared as a signal in both programs. STEP-1 reported cholelithiasis in 1.6% of semaglutide participants versus 0.7% placebo [5]. Rapid weight loss itself promotes gallstone formation, and this risk exists with any effective obesity treatment. Patients with a prior history of gallbladder disease should be counseled accordingly before starting either agent.

Muscle mass loss is a growing clinical concern across both drug classes. Roughly 25 to 40% of weight lost during GLP-1 therapy may come from lean mass rather than fat, based on DEXA sub-studies in SURMOUNT and STEP trials. Resistance training and adequate protein intake (≥1.2 g/kg of ideal body weight per day) are the current standard recommendations to mitigate lean mass loss, though no large RCT has yet established the optimal protocol during GLP-1 therapy specifically.

Head-to-Head Summary Table: SURMOUNT vs. STEP Key Numbers

| Trial | Drug | Population | Duration | Mean Weight Loss (Active) | Mean Weight Loss (Placebo) | |---|---|---|---|---|---| | SURMOUNT-1 | Tirzepatide 15 mg | No T2D | 72 wk | 22.5% | 2.4% | | SURMOUNT-2 | Tirzepatide 15 mg | T2D | 72 wk | 15.7% | 3.3% | | SURMOUNT-3 | Tirzepatide (any dose) | No T2D, post-lifestyle run-in | 72 wk (+12 wk run-in) | 26.6% cumulative | 9.4% cumulative | | SURMOUNT-4 | Tirzepatide continuation | No T2D | 88 wk total | 25.4% (continuation) | 9.9% (withdrawal) | | STEP-1 | Semaglutide 2.4 mg | No T2D | 68 wk | 14.9% | 2.4% | | STEP-2 | Semaglutide 2.4 mg | T2D | 68 wk | 9.6% | 3.4% | | STEP-3 | Semaglutide 2.4 mg | No T2D | 68 wk | 16.0% | 5.7% | | STEP-5 | Semaglutide 2.4 mg | No T2D | 104 wk | 15.2% | 2.6% |

What Prescribers and Patients Should Take From This Data

SURMOUNT-3's 26.6% cumulative weight loss figure is the highest pharmacotherapy-only number in any published Phase 3 trial, but it reflects a patient who first completed 12 weeks of intensive lifestyle intervention. Reproducing that result in practice requires that the lifestyle component be real, not pro forma. The 12-week run-in in SURMOUNT-3 used a low-calorie meal replacement program with behavioral counseling sessions.

The STEP trials show that semaglutide works at meaningful scale without a required pre-treatment phase. STEP-3 adds that intensive behavioral therapy on top of semaglutide yields 16.0% weight loss, compared with 14.9% in STEP-1 without mandatory intensive counseling, suggesting a modest but real additive effect.

For any patient starting either drug, the current Wegovy or Zepbound label dose-escalation schedules are not optional. Skipping titration steps is the single most common cause of premature discontinuation due to nausea, and early discontinuation is the most common reason patients miss the weight loss numbers reported in trials.

Obesity medicine specialists typically define treatment success as at least 5% weight loss at 12 weeks on the maximal tolerated dose. Patients who do not reach that threshold by 12 to 16 weeks on the starting maintenance dose may not be responders, and dose escalation or agent change should be discussed.

The full-dose 15 mg tirzepatide maintenance dose was the dose associated with maximal weight loss across SURMOUNT-1 and SURMOUNT-3. Patients who tolerate escalation to 15 mg and are not meeting response thresholds at 10 mg should have that conversation with their prescriber before assuming the drug is not working.